Tiziana Life Sciences Share Discussion Threads

[jpuff] 18/4/2024 20:13

It was always a high risk high reward punt or zilch

[jpuff] 18/4/2024 18:48

Well I need a dollar to prevent Nasdaq delist. Hope you're right!

[lean5gb] 18/4/2024 18:37

Bottomed at $0.5. Traders now moving theit profits back in. This is looking like a 'bagger' from here on.

[jpuff] 18/4/2024 17:47

Well I can't predict the future but. I've decided to hold tight. If I lose so be it

[lean5gb] 18/4/2024 17:32

The traders have arrived jpuff. Its all about profit, end of. The share price will either hit $1 by june, or they will delist. Do ya feel lucky? . Well, do you ?

[jpuff] 18/4/2024 17:27

Ah well it's a bit of fun at times then the aerial disappointment returns

[lean5gb] 18/4/2024 17:24

'Keep the faith' in, the 'can kicking' bods, or the share price hitting $1 ?.

[jpuff] 18/4/2024 16:26

Up 50% now - keep the faith peeps!

[lean5gb] 18/4/2024 16:13

Just be happy to sell at $1 in june before the inevitable drop again. ;0)))) We aim to please .?

[jpuff] 18/4/2024 16:04

We're on our way! Fill yer boots!

[marcus80] 07/4/2024 19:53

hxxps://www.biospace.com/article/biotech-bankruptcies-skyrocket/

delisting this month imo !

[2seabass] 27/3/2024 20:21

Its heading for share consolidation. Prop 3 or 4 for one new. We all got consolidated already 2 for 1 when delisted from LSE onto Nasdaq.
Then out comes the fund raise !!
Been shafted

[lean5gb] 26/3/2024 17:02

Nasdaq $1 delisting rule?If a company trades for 30 consecutive business days below the $1.00 minimum closing bid price requirement, Nasdaq will send a deficiency notice to the company, advising that it has been afforded a "compliance period" of 180 calendar days to regain compliance with the applicable requirements.. How has this company not delisted yet?

[lean5gb] 17/3/2024 15:40

Another 'begging bowl' meethinks... Then, lights out!

[marcus80] 17/3/2024 12:35

hxxps://www.biospace.com/article/biotech-bankruptcies-skyrocket/

bankruptcies skyrocket!! tiziana next !

[jpuff] 05/3/2024 21:26

NEW YORK, March 5, 2024 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced that Dr. Howard Weiner will present positive data of intranasal anti-CD3 monoclonal antibody in models of Alzheimer's and Parkinson's disease at AD/PD, March 5-9, 2024. AD/PD is the annual International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders in Lisbon, Portugal. Presentation Information Presenter: Howard L Weiner, M.D.Title: Nasal immunotherapy of the Monocyte-Microglial axis to treat Alzheimer's DiseaseDay: Friday, March 8thTime: 15:05 UTCLocation: Auditorium V Howard L. Weiner, M.D., Co-Director of the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital, a founding member of Mass General Brigham, and Chairman of Tiziana's Scientific Advisory Board, stated, "I believe that the modulation of innate immunity via targeting microglia will play a synergistic role with the currently approved anti-amyloid Alzheimer's treatments. Our research has demonstrated that intranasal rodent anti-CD3 mAb and intranasal fully human anti-CD3 mAb (foralumab) will decrease microglia activation in rodents and humans, respectively. Nasal anti-CD3 has also shown to reduce hemorrhage and edema that occurs with ARIA" "With the focus on effective Alzheimer's disease treatments and we have the potential to be a novel, first in class neuroinflammatory modulator," commented Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences. "Our intranasal approach has large potential as it does not target beta-amyloid or other proteins, but focuses on the neuroinflammatory process itself, which may be complementary or synergistic with existing FDA approved treatments. The data also excitingly shows a reduction of hemorrhage and edema that occurs with ARIA."

[marcus80] 06/2/2024 07:35

@jpuff long time ago! Still sooo bullish about GC like a year ago 😜

[marcus80] 06/2/2024 07:28

Probably OTC soon! Game over

[lean5gb] 31/1/2024 21:44

6 Oct '21 - 22:20 - 17234 of 17784
0 0 0
Puff, you've been here for a considerable period of time and long before many of us, are you seriously buying into this even now?

...Don't become sentimental with your investing, it will destroy what sanity you have believe me.

[lean5gb] 31/1/2024 20:51

Just popped in to say hi, after 10 months leave.
.
What's happening peeps?

[jpuff] 16/10/2023 16:37

Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal ForalumabOctober 16, 2023 at 7:00 AM EDTNumeric improvements were seen across key multiple sclerosis measures, including the Modified Fatigue Impact Scale, Expanded Disability Status Scale, Timed 25-Foot Walk test, Pyramidal Scores and NeuroQoL™ Fatigue scores.Data was presented at ECTRIMS (39th Congress of the European Committee for Treatment and Research of Multiple Sclerosis) on October 11, 2023NEW YORK, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced six-month data showing positive clinical improvements related to Modified Fatigue Impact Scale (MFIS) scores and similar important clinical measures of physical function in foralumab-treated, non-active Secondary Progressive Multiple Sclerosis (na-SPMS) patients participating in an Expanded Access (EA) Program. This follows on from previously announced positive six-month PET scan data which was presented at ECTRIMS 2023.The findings, which are summarized in table 1 below, show broad based six month improvements across various key measures for multiple sclerosis. Secondary progressive multiple sclerosis is hallmarked by an increase of disability over time. The table below shows a stabilization or an improvement in physical function of the various clinical measures over a six-month period.Table 1 EDSS Pyramidalscore T25FW MFISEA1 - ? - -EA2 ? - ? ?EA3 - - ? -EA4 ? - - ?EA5 - ? ? ?EA6 - - - ?- Denotes stabilization? Denotes improvement Fatigue, as measured above in MFIS, refers to an overwhelming sense of physical, mental, and emotional exhaustion that is disproportionate to the level of activity or effort exerted. It is a major, common, and often debilitating symptom experienced by many individuals with MS. It differs from the typical tiredness that everyone experiences from time to time. In the context of MS, it is called 'primary fatigue' and is a direct result of damage to the central nervous system. This kind of fatigue can significantly impact a person's daily life and functioning."I am pleased to see the continued clinical response to intranasal foralumab from patients enrolled in our expanded access na-SPMS program," stated Dr. Tanuja Chitnis, M.D., Principal Investigator and Professor of Neurology at Harvard Medical School (HMS) and senior neurologist at Brigham and Women's Hospital, a founding member of Mass General Brigham Healthcare System. "Notably, in this latest clinical update for patients EA 3 through EA 6, we have seen improvement in the Modified Fatigue Impact Scale scores in three out of four patients, which is significant since fatigue is a major complaint in this population. We have also seen various degrees of improvement in the Expanded Disability Status Scale, Timed 25-Foot Walk Test, pyramidal function scores and NeuroQoL Fatigue scores in a disease state that typically shows a decline in function over time. Howard L. Weiner, M.D., Chairman of Tiziana's Scientific Advisory Board and Co-Director of the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital noted, "With six patients now dosed in our na-SPMS Expanded Access Program and followed over a six-month period, we are seeing a highly encouraging efficacy signal in this difficult-to-treat patient population."Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences noted "Intranasal foralumab is continuing to show clinical improvements over time in patients with na-SPMS where foralumab targets inflammation in the brain. Based on the totality of the clinical results seen to-date, I am hopeful that intranasal foralumab and its anti-inflammatory mechanism of action could provide relief to na-SPMS patients that currently have no available therapies."About ForalumabActivated T cells play an important role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds to the T cell receptor and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets. This effect has been demonstrated in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects. The non-active SPMS intranasal foralumab Phase 2 trial is expected to start screening in November of 2023. Immunomodulation by nasal anti-CD3 mAb represents a novel avenue for treatment of neuroinflammatory and neurodegenerative human diseases.1,2About Tiziana Life SciencesTiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana's innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana's lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana's technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.For further inquiries:Tiziana Life Sciences LtdPaul Spencer, Business Development and Investor Relations [phone]email: [e-mail]:Irina KofflerLifeSci Advisors, LLC+1 646 970 [e-mail]1 https://www.pnas.org/doi/10.1073/pnas.22202721202 https://www.pnas.org/doi/10.1073/pnas.2309221120

[jpuff] 13/10/2023 12:26

On October 13, 2023, Tiziana Life Sciences LTD (the "Company") issued a press release, announcing that a reduction in activated microglia, as seen in six-month Positron Emission Tomography (PET) scans, has now been observed in a total of five of the six patients with non-active secondary-progressive multiple sclerosis (na-SPMS) treated with intranasal foralumab in its Expanded Access Program (EAP). Activated microglia are believed to play a prominent role in the pathogenesis of neuroinflammatory and neurodegenerative diseases including multiple sclerosis, Alzheimer's disease, and amyotrophic lateral sclerosis, or ALS.

[jpuff] 06/9/2023 13:17

Study Validating MoA of Intranasal Foralumab in Alzheimer's Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance